FCN-338 - CAS 2248046-39-9

FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor, exhibiting an IC50 of 4.5 nM for the Bcl-2/BAK interaction. It effectively suppresses tumor growth in mouse models of follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenografts without causing significant weight loss. FCN-338 demonstrates broad-spectrum anticancer activity, making it suitable for treating FL, chronic lymphocytic leukemia (CLL) /small lymphocytic leukemia (SLL), AML, and ALL.

Bcl-2 Family

Apoptosis

2247998

C48H48ClN7O7S

902.46

N(=O)(=O)C1=C2C(=CC(S(NC(=O)C3=C(OC=4C=C5C(=NC4)NC=C5)C=C(C=C3)N6CCN(CC7=C(CC(C)(C)CC7)C8=CC=C(Cl)C=C8)CC6)(=O)=O)=C1)OC[C@H](CC9=CC=CC=C9)N2

-20°C

Ice Packs

Small Compound